Changing trends in infectious disease in heart transplantation

Haddad, François; Deuse, T.; Pham, Michael; Khazanie, Prateeti; Rosso, Fernando; Luikart, Helen; Valantine, Hannah A.; Leon, Sebastian; Vu, Tai Anh; Hunt, Sharon A.; Oyer, Philip E.; Montoya, José G.

doi:10.1016/j.healun.2009.08.018

Cited by 46 publications

(45 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most incidents have pulmonary complications and rarely fatal CNS involvements (7). On the basis of the search of the entire Medline database, including the in-process file, cases of nocardiosis in the setting of mycophenolate mofetil, which our patient was on, have only been limited to patients with non-lupus renal and heart transplant (8,9). No cases of nocardiosis have ever been reported in patients with lupus on mycophenolate mofetil, hydroxychloroquine, or isoniazid.…”

Section: Discussionmentioning

confidence: 98%

A case of central nervous system nocardiosis in a patient with lupus treated with belimumab

2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

A case of central nervous system nocardiosis in a patient with lupus treated with belimumab

2017

View full text Add to dashboard Cite

“…Des tendances épidémiologiques récentes se dégagent du fait des changements de stratégies de l'immunosupression depuis les années 1980 et de la mise en place systématique de préventions au long cours [11,12]. La fréquence et la sévérité des infections bactériennes communautaires classiques et opportunistes, et celles liées aux soins se modifi ent.…”

Section: La Nocardioseunclassified

“…Les stratégies générales de prévention (vaccination, prophylaxie universelle et/ou ciblée, traitements préemptifs) ont modifi é l'incidence et la sévérité des épisodes infectieux graves après transplantation [1,2,11]. L'immunisation réelle du receveur contre certaines infections, virales ou bactériennes, doit être évaluée avant transplantation (oreillons, rougeole, rubéole, diphtérie, tétanos, VHB, polio, varicelle, Haemophilus infl uenza, pneumocoque), et des vaccinations adaptées sont à mettre en oeuvre avant inscription sur liste (l'effi cacité immunologique du vaccin est plus limitée dans le temps et dans le spectre par comparaison avec le sujet sain).…”

Section: Mesures Généralesunclassified

Prise en charge des infections chez les adultes transplantés d’organe(s)

Schneider

Guillot

Chomette

et al. 2013

Références en Réanimation. Collection De La SRLF

View full text Add to dashboard Cite

“…This agent is not only effective for protection against P. jirovecii, but also against Toxoplasma gondii. Alternatively, oral combinations of pyrimethamine and sulfadoxine or agents such as dapson may be utilized [19] .…”

Section: Resultsmentioning

confidence: 99%

“…It is one of the most commonly used agents for this indication since 1988, when it was first introduced for use in PP. While in the initial years, a recommendation to use TMP/SMX for the first 3 or 13 mo was made, after 1997 the recommended duration of prophylaxis has been extended as to include a prophylaxis of several years to life-long prophylaxis [19] . TMP/SMX has been shown to reduce the risk of PCP by more than 90% [32] .…”

Section: Agents Used For Prophylaxismentioning

confidence: 99%

Pentamidine inPneumocystis jiroveciiprophylaxis in heart transplant recipients

Diken¹,

Diken²,

Hanedan³

et al. 2016

WJT

View full text Add to dashboard Cite

Despite advances in transplantation techniques and the quality of post-transplantation care, opportunistic infections remain an important cause of complications.Pneumocystis jirovecii (P. jirovecii ) is an opportunistic organism, represents an important cause of infections in heart transplantation patients. Almost 2% to 10% of patients undergoing cardiac transplantation have Pneumocystis pneumonia. Prophylaxis is essential after surgery. Various prophylaxis regimes had been defined in past and have different advantages. Trimethoprim/sulfamethoxazole (TMP/SMX) has a key role in prophylaxis against P. jirovecii . Generally, although TMP/SMX is well tolerated, serious side effects have also been reported during its use. Pentamidine is an alternative prophylaxis agent when TMP/SMX cannot be tolerated by the patient. Structurally, pentamidine is an aromatic diamidine compound with antiprotozoal activity. Since it is not effectively absorbed from the gastrointestinal tract, it is frequently administered via the intravenous route. Pentamidine can alternatively be administered through inhalation at a monthly dose in heart transplant recipients. Although, the efficiency and safety of this drug is well studied in other types of solid organ transplantations, there are only few data about pentamidine usage in heart transplantation. We sought to evaluate evidence-based assessment of the use of pentamidine against P. jirovecii after heart transplantation.

show abstract

Changing trends in infectious disease in heart transplantation

Cited by 46 publications

References 51 publications

A case of central nervous system nocardiosis in a patient with lupus treated with belimumab

A case of central nervous system nocardiosis in a patient with lupus treated with belimumab

Prise en charge des infections chez les adultes transplantés d’organe(s)

Pentamidine inPneumocystis jiroveciiprophylaxis in heart transplant recipients

Contact Info

Product

Resources

About